Multiple myeloma (MM) is a plasma cell malignancy which accounts for approximately 10% of hematologic malignancies. Despite the introduction of new therapeutic agents, MM remains incurable and nearly all patients ultimately relapse. About 20% of MM are due to a chromosomal translocation t(4;14) leading to overexpression of the NSD2 histone methyltransferase. NSD2 catalyzes dimethylation of lysine 36 on histone H3 (H3K36me2) and is associated with transcriptionally active regions. Several studies have shown that in MM harboring the translocation t(4;14), oncogenic programming is dependent on the methyltransferase activity of NSD2. Thus, NSD2 is a potential therapeutic target for MM for which no curative treatment is available to date. In addition, the NSD2 overactivity is also observed in prostate and lung cancers. To address these medical needs, Inventiva has started a drug discovery program on NSD2 inhibitors.
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To our knowledge, no NSD2 inhibitor have been identified to date despite several screening effort performed by other groups. Our library has already produced new chemical starting points for other KMTs, and we believe that our hits could be promising starting points to generate potent and selective NSD2 inhibitors.
The assay is based on AlphaLISA technology and relies on the detection of H3K36me2 marks on nucleosome by a specific antibody. In parallel to the biochemical screening, we are developing secondary cellular assays based on the H3K36me2 methylation and proliferation to further confirm hit activity.
4-INVENTIVA LIBRARY: IVALib
Library available for external partnerships Chaetocin, a non specific inhibitor, is able to block NSD2 activity in a dose dependent manner, with an IC50 of 635 nM, similar to the ones described in the literature.
